il12

由GHaskó著作·1999·被引用98次—Interleukin-12(IL-12)isapivotalcytokineindrivingtheimmunesystemtowardsaThelper(Th)1typeresponseandpreventingaTh2typeimmuneprofile.,介白質十二(Interleukin-12,IL-12)是異二聚體(heterodimer)細胞激素,由p35和p40亞基(subunit)組成,主要會促進第1型輔助性T細胞(Thelper1cells,TH1)的分化 ...,Interleukin12(IL-12)isaninterleukinthatisnaturallyproducedbydendriticcells,macrophag...

IL

由 G Haskó 著作 · 1999 · 被引用 98 次 — Interleukin-12 (IL-12) is a pivotal cytokine in driving the immune system towards a T helper (Th)1 type response and preventing a Th2 type immune profile.

IL-12-IL

介白質十二(Interleukin-12, IL-12) 是異二聚體(heterodimer) 細胞激素,由p35和p40亞基(subunit) 組成,主要會促進第1型輔助性T細胞(T helper 1 cells, TH1)的分化 ...

Interleukin 12

Interleukin 12 (IL-12) is an interleukin that is naturally produced by dendritic cells, macrophages, neutrophils, helper T cells and human B-lymphoblastoid ...

Interleukin 12 - an overview

IL-12 is a Th1 cytokine that is predominantly generated by cells in the innate immune system. Its role is associated with the differentiation of naïve T cells ...

Interleukin 12 a Key Immunoregulatory Cytokine in ...

由 T Hamza 著作 · 2010 · 被引用 455 次 — Interleukin 12 (termed IL-12p70 and commonly designated IL-12) is an important immunoregulatory cytokine that is produced mainly by antigen-presenting cells ...

Interleukin

由 G Trinchieri 著作 · 2003 · 被引用 4693 次 — Interleukin-12 (IL-12) is a heterodimeric pro-inflammatory cytokine that regulates T-cell and natural killer-cell responses, induces the ...

Interleukin-12

由 J Liu 著作 · 2005 · 被引用 144 次 — Interleukin-12 (IL-12) is a heterodimeric cytokine composed of the p35 and p40 subunits. It is produced by antigen-presenting cells and plays a critical ...

Localized Interleukin

由 KG Nguyen 著作 · 2020 · 被引用 251 次 — Interleukin-12 (IL-12) is a potent, pro-inflammatory type 1 cytokine that has long been studied as a potential immunotherapy for cancer.

我該選擇p40或是p70 ELISA kit 偵測IL

2019年6月4日 — IL-12 是由p35 和p40 兩個subunit 所組成約70~75kDa 的二聚體醣蛋白質,很多細胞都能生成p35,但是只有被活化的monocyte/marcophage 才能生成p40。

改良版IL

2020年4月17日 — 研究團隊認為修飾後的CBD–IL-12 改變原本IL-12 的特性,將有望突破現有免疫治療的瓶頸,擴大免疫治療在多種癌症上的臨床應用效果。